PRUTECH RESEARCH & DEVELOPMENT PARTNERSHIP III
8-K, 1997-01-21
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: SCUDDER GLOBAL FUND INC, 497, 1997-01-21
Next: EQUIPMENT LEASING CORPORATION OF AMERICA, POS AM, 1997-01-21



<PAGE>

            SECURITIES AND EXCHANGE COMMISSION
                Washington, D.C. 20549

                       FORM 8-K
                    CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 7, 1997

                        Commission file number:  0-20081

                 PruTech Research and Development Partnership III
- -------------------------------------------------------------------------------
               (Exact name of Registrant as specified in its charter)

California                                             77-0129484
- -------------------------------------------------------------------------------
(State or other jurisdiction of                        (I.R.S. Employer
incorporation or organization)                         Identification No.)

440 Mission Court, Suite 250, Fremont, California             94539
- -------------------------------------------------------------------------------
(Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code: (510) 656-1855

                                    N/A                                        
- -------------------------------------------------------------------------------
           Former name, former address and former fiscal year,
                       if changed since last report.

<PAGE>

Item 2 - Aquisition or Disposition of Assets

    During the period from December 13, 1996 through January 7, 1997, the 
Registrant sold 430,298 shares of Creative BioMolecules, Inc. common stock on 
the open market for an aggregate price of approximately $4,565,000.  The sales 
resulted in a cumulative realized gain for both financial reporting and income 
tax purposes of approximately $3,157,000.  An unrealized gain of approximately 
$1,658,000 relating to these shares (which was reported as a separate 
component of partners' capital at September 30, 1996) was reversed as a result 
of the sales.

<PAGE>

                            SIGNATURES

   Pursuant to the requirements of the Securities Exchange Act of 1934, the 
Registrant has duly caused this report to be signed on its behalf by the 
undersigned hereunto duly authorized.

PruTech Research and Development Partnership III

By:  R&D Funding Corp
     A Delaware corporation, General Partner

By: /s/ Steven Carlino                      Date: January 21, 1997
- ------------------------------
Steven Carlino
Vice President
Chief Accounting Officer for the Registrant


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission